rHCT3-1

rHCT3-1 appears to be a code name for a compound within the rHCT3 molecular platform developed by Theialife, an ophthalmology company. The rHCT3 platform is designed to address various unmet needs in ophthalmology, including conditions like neovascular age-related macular degeneration, pterygium, keratoconus, and corneal blindness. While specific details for rHCT3-1 are not publicly available, a related compound, rHCT3-2, is being developed as an eye drop for keratoconus, acting by promoting collagen crosslinking and inhibiting metalloproteinases. Theialife also has lead assets like ND10 and 7MX for pediatric myopia, which function as non-selective antagonists of adenosine receptors. Given the lack of specific information, rHCT3-1 is likely an early-stage or internal designation within this broader platform.